via telegraph.co.uk
Last year, drug sales were at an all-time high of $856bn (£535bn), but only 5pc of those sales were driven by products launched within the last five years. The struggle companies face in reinvigorating their portfolios was illustrated by the number of "new molecular entities" launched last year dropping to 21, down from 26 in 2009.
Meanwhile, the number of potential new drugs entering Phase I and II trials fell by 47pc and 53pc respectively, compared to 2007.
CMR said the number of drugs failing at the latter stages of trials should be "of particular concern to the industry", with 55 Phase III proj-ects being terminated in 2007-09 and 2008-10, more than double
the number terminated in 2005-07.
No comments:
Post a Comment